CYBERDYNE : Announcement of Financial Results for the Six Months ended September 30, 2022 (IFRS)

Notice: The Company issues 77,700,000 Class B Shares that hold equal rights regarding distributions of surplus and distribution of residual assets as Common Shares, but differ in the number of shares that constitute one unit (10 shares). Any holder of Common Shares or Class B Shares constituting one or more units is entitled to one voting right for each unit. Accordingly, a shareholder of Class B Shares has 10 times as many voting rights as a shareholder of Common Shares when they have the equal number of shares. Class B Shares are held by Dr. Yoshiyuki Sankai, the Sankai Health Foundation and the Sankai Science and Technology Promotion Foundation, both of which are represented and managed by Dr. Yoshiyuki Sankai, as well as with the trustees, directors or controllers of the foundations. This dual class structure reflects the concentration of voting rights with Dr. Yoshiyuki Sankai and the foundations, for the purpose of ensuring the Company's advanced technologies are used for peaceful purposes, and preventing the misuse of these technologies to harm humans or to create military weapons. Dr. Yoshiyuki Sankai directly and indirectly holds approximately 85.3% of the total number of voting rights as of March 31, 2018.